Neidio i’r brif dudalen lywio
Neidio i chwilio
Neidio i’r prif gynnwys
Trefnu yn ôl
Keyphrases
Low Molecular Weight Heparin
100%
Fragmin
100%
Lung Cancer
100%
Phase I Trial
100%
Dalteparin
75%
Venous Thromboembolism
75%
Patient Will
50%
Disease Progression
25%
Cost-effectiveness
25%
Non-small Cell
25%
Arterial Circulation
25%
Patients with Cancer
25%
Treatment Group
25%
Carers
25%
Self-administer
25%
Phase II Trial
25%
Ratio Standard
25%
Pulmonary Embolism
25%
Metastasis
25%
Thrombus
25%
Breathlessness
25%
Pulmonary Arterial
25%
Serious Adverse Events
25%
Radiotherapy
25%
Event-free Survival
25%
Venous Thromboembolic Events
25%
Overall Survival
25%
Quality of Life
25%
Deep Vein Thrombosis
25%
Cytological Diagnosis
25%
Deep Vein
25%
Anticancer Effect
25%
Chemotherapy
25%
Small Cell
25%
Metastasis-free Survival
25%
Bronchioloalveolar Carcinoma
25%
Blood Clot
25%
Cost-utility
25%
Primary Outcome Measure
25%
Subcutaneous Injection
25%
Level of Life
25%
Method Design
25%
Secondary Outcome Measures
25%
Histopathological Diagnosis
25%
Medicine and Dentistry
Dalteparin Sodium
100%
Lung Cancer
100%
Clinical Trial
100%
Low Molecular Weight Heparin
100%
Venous Thromboembolism
75%
Health Care Cost
50%
Phase III Trials
25%
Dyspnea
25%
Metastasis Free Survival
25%
Deep Vein Thrombosis
25%
Subcutaneous Injection
25%
Event Free Survival
25%
Radiation Therapy
25%
Thrombus
25%
Quality of Life
25%
Overall Survival
25%
Treatment Group
25%
Pelvis
25%
Cytodiagnosis
25%
Adverse Event
25%
Pulmonary Embolism
25%
Small Cell Lung Cancer
25%
Blood Clot
25%
Metastatic Carcinoma
25%
Disease Exacerbation
25%
Arterial Circulation
25%
Chemotherapy
25%
Nursing and Health Professions
Lung Cancer
100%
Clinical Trial
100%
Dalteparin
100%
Low Molecular Weight Heparin
100%
Venous Thromboembolism
75%
Randomization
50%
Adverse Event
25%
Quality of Life
25%
Dyspnea
25%
Radiotherapy
25%
Treatment Group
25%
Event Free Survival
25%
Disease Exacerbation
25%
Cost Utility Analysis
25%
Small Cell Lung Cancer
25%
Deep Vein Thrombosis
25%
Chemotherapy
25%
Thrombus
25%
Subcutaneous Injection
25%
Lung Embolism
25%
Overall Survival
25%
Metastasis Free Survival
25%
Cytodiagnosis
25%
Anticancer
25%
Pharmacology, Toxicology and Pharmaceutical Science
Dalteparin
100%
Clinical Trial
100%
Low Molecular Weight Heparin
100%
Lung Cancer
100%
Venous Thromboembolism
75%
Event Free Survival
25%
Treatment Group
25%
Overall Survival
25%
Phase III Trials
25%
Subcutaneous Injection
25%
Deep Vein Thrombosis
25%
Lung Embolism
25%
Small Cell Lung Cancer
25%
Metastasis Free Survival
25%
Disease Exacerbation
25%
Dyspnea
25%
Thrombus
25%
Malignant Neoplasm
25%
Adverse Event
25%
Chemotherapy Regimen
25%